Loading field map
A veterinarian treating a dog with a chronic cough must decide: is the problem an infectious disease, a heart condition, or a side effect of a long-term medication? The answer determines whether the treatment is an antibiotic, a cardiac drug, or a change in therapy. But that single clinical decision sits at the intersection of several deeper questions. How does disease in a companion animal resemble disease in humans, and how does it differ? What counts as reliable evidence for a treatment in a species that has not been studied in large clinical trials? Should the veterinarian consider only the individual patient, or also the risk that an antibiotic might contribute to resistance that affects other animals and people? Over the past century, companion animal medicine has developed five major frameworks that address these questions, each building on, reacting to, or coexisting with the others.
Before companion animal medicine had its own identity, veterinarians borrowed heavily from human medicine. The framework of comparative pathology, which took shape in the early twentieth century, treated disease as a biological phenomenon that could be studied across species. A tumor in a dog, a bacterial infection in a cat, and a metabolic disorder in a horse were seen as variations on processes already described in human patients. This approach gave companion animal practitioners a ready-made diagnostic vocabulary and a set of methods—necropsy, histopathology, bacteriology—that had been developed in medical schools and research institutes.
Comparative pathology was not a treatment framework; it was an infrastructure for understanding what was wrong. Its great strength was that it allowed veterinarians to recognize patterns: a coughing dog with radiographic changes in the lungs could be understood through the same pathological categories used for human pneumonia. Its limitation was that it said little about how to intervene. A diagnosis of heartworm disease, for example, told the clinician what was happening but not which drug to use or at what dose. That gap would be filled by the next framework.
By mid-century, companion animal practice had moved beyond diagnosis into active treatment. The framework of veterinary pharmacology and therapeutics emerged to address a practical problem: drugs developed for humans often did not work the same way in dogs, cats, or birds. Species differences in metabolism, excretion, and sensitivity meant that a safe human dose could be toxic in a cat or ineffective in a dog. This framework’s core contribution was the systematic study of species-specific pharmacokinetics and pharmacodynamics.
Veterinary pharmacology and therapeutics transformed companion animal medicine from a diagnostic enterprise into a therapeutic one. It provided dosing guidelines, safety profiles, and efficacy data for common drugs—antibiotics, anesthetics, anti-inflammatories, heartworm preventives—tailored to the species most often seen in practice. It also introduced the idea that treatment decisions should be based on controlled studies, not just clinical intuition or extrapolation from human medicine. In this sense, it laid the groundwork for the evidence-based movement that would follow, though its methods were still relatively informal: much of the early data came from small case series, manufacturer trials, and expert consensus rather than randomized controlled trials.
While pharmacology was expanding the veterinarian’s ability to treat disease, a separate line of inquiry was asking whether treating disease was enough. Animal welfare science, which began to coalesce in the 1960s, argued that the goal of veterinary care should not be merely the absence of disease but the presence of positive well-being. This framework introduced concepts that had no place in comparative pathology or pharmacology: pain as a subjective experience, behavioral needs, affective states, and quality of life.
For companion animal medicine, welfare science had several concrete effects. It pushed clinicians to recognize and treat pain in species that cannot report it, leading to the development of species-specific pain scales and analgesic protocols. It raised questions about the ethics of procedures—declawing, tail docking, elective surgery—that had previously been routine. And it broadened the scope of clinical attention beyond the biomedical to include behavior, environment, and the human-animal bond. Welfare science did not replace pharmacology or pathology; it coexisted with them, adding a layer of ethical and affective concern that earlier frameworks had ignored.
By the 1990s, companion animal practitioners had access to a growing arsenal of drugs and surgical techniques, but they also faced a problem: how to tell which interventions actually worked. Much of what was taught in veterinary schools and practiced in clinics rested on tradition, expert opinion, or extrapolation from human medicine. Evidence-based veterinary medicine (EBVM) emerged as a methodological framework that demanded systematic appraisal of research evidence.
EBVM borrowed its core structure from human evidence-based medicine: a hierarchy of evidence that places systematic reviews and randomized controlled trials above case reports and expert opinion. For companion animal medicine, this created a tension. Large randomized trials are expensive and difficult to conduct in dogs and cats, and much of the existing literature consisted of small studies with weak designs. EBVM did not reject pharmacology or pathology; instead, it reframed them as sources of evidence that needed to be critically evaluated. A drug that had been used for decades might turn out, under EBVM scrutiny, to have little evidence of efficacy, while a newer treatment with a strong trial might become the standard of care.
EBVM also intersected with animal welfare science in an interesting way. Welfare science had introduced subjective outcomes—pain, distress, quality of life—that are harder to measure than tumor size or infection status. EBVM’s emphasis on rigorous measurement pushed welfare researchers to develop validated instruments for these outcomes, such as owner-completed questionnaires and standardized behavioral assessments. The two frameworks thus reinforced each other, even though they came from different starting points.
The most recent framework, One Health, expanded the scope of companion animal medicine beyond the individual patient to include human and environmental health. One Health is not a rejection of earlier frameworks but a transdisciplinary reorientation. It argues that the health of people, animals, and ecosystems are interconnected, and that effective clinical practice must account for these connections.
For companion animal medicine, One Health has several specific implications. Zoonotic diseases—rabies, leptospirosis, toxoplasmosis—become not just animal health problems but public health problems that require coordinated action. Antimicrobial resistance, driven in part by antibiotic use in companion animals, links individual prescribing decisions to population-level risks. The human-animal bond, long recognized by welfare science, is reframed as a health determinant: pet ownership can improve human mental and physical health, but it also creates pathways for disease transmission.
One Health also challenges the patient-centered ethos of earlier frameworks. A veterinarian deciding whether to prescribe antibiotics for a cat with a urinary tract infection must now weigh the individual cat’s benefit against the societal risk of resistance. This is a genuine tension, not a theoretical one. Research on antibiotic use in UK companion animal practice, including studies of phage therapy as an alternative, illustrates how One Health thinking is reshaping clinical decisions.
Today, three frameworks remain active in companion animal medicine: animal welfare science, evidence-based veterinary medicine, and One Health. They coexist in a pluralist landscape where their assumptions sometimes align and sometimes conflict.
They agree on several points. All three reject the idea that clinical decisions should be based solely on tradition or authority. All three recognize that companion animals are sentient beings whose subjective experience matters. And all three acknowledge that veterinary practice operates within a broader social and ecological context.
But they disagree on what counts as the most important evidence and whose interests should take priority. EBVM privileges controlled studies and systematic reviews; welfare science often relies on behavioral and affective indicators that are harder to quantify; One Health introduces population-level and ecological outcomes that may conflict with individual patient welfare. A concrete example: a dog with a chronic skin infection might benefit from long-term antibiotics, but EBVM might find the evidence for that approach weak, welfare science might worry about the dog’s quality of life on repeated vet visits, and One Health might flag the resistance risk. The clinician must navigate these competing considerations without a single framework telling them what to do.
This pluralism is not a weakness. Each framework captures something real about the practice of companion animal medicine: the need to understand disease, the power of targeted treatment, the ethical demand to consider well-being, the discipline of rigorous evidence, and the recognition that individual health is embedded in larger systems. The history of the subfield is the story of these frameworks accumulating, interacting, and sometimes pulling in different directions—a productive tension that continues to shape how veterinarians care for the animals that share our lives.